biostudies-literatureDevan ARAmrita Vishwa Vidyapeetham Research SEED grant656https://www.ebi.ac.uk/biostudies/studies/S-EPMC8308499biostudies-literatureUnknown14(7)Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to tackle HCC are based on oral multi-kinase inhibitors like sorafenib; however, the clinical use of the drug is restricted due to the limited survival rate and significant side effects, suggesting the existence of a primary or/and acquired drug-resistance mechanism. Because of this hurdle, HCC patients are forced through incomplete therapy. Although multiple approaches have been employed in parallel to overcome multidrug resistance (MDR), the results are varying with insignificant outcomes. In the past decade, cancer immunotherapy has emerged as Pharmaceuticals (Basel, Switzerland)Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma.PMC8308499Project ID: K-PHAR-20-627Kumar ARNath LRDevan ARAnto NPKim HMuraleedharan ANair BMathew BfalseInsights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma.Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to tackle HCC are based on oral multi-kinase inhibitors like sorafenib; however, the clinical use of the drug is restricted due to the limited survival rate and significant side effects, suggesting the existence of a primary or/and acquired drug-resistance mechanism. Because of this hurdle, HCC patients are forced through incomplete therapy. Although multiple approaches have been employed in parallel to overcome multidrug resistance (MDR), the results are varying with insignificant outcomes. In the past decade, cancer immunotherapy has emerged as 2021-01-01T00:00:00Z2021 Jul2025-04-04T07:17:41.914Z2022-02-11T05:07:04.042ZS-EPMC83084993435808210.3390/ph14070656